Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Change in Receivables (2017 - 2025)

Akebia Therapeutics (AKBA) has disclosed Change in Receivables for 9 consecutive years, with -$19.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables fell 721.28% to -$19.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $14.1 million, a 449.53% increase, with the full-year FY2025 number at $14.1 million, up 449.53% from a year prior.
  • Change in Receivables was -$19.1 million for Q4 2025 at Akebia Therapeutics, down from -$6.2 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $27.9 million in Q1 2025 to a low of -$58.7 million in Q3 2022.
  • A 5-year average of $1.1 million and a median of $3.0 million in 2023 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: soared 7399.56% in 2022, then tumbled 721.28% in 2025.
  • Akebia Therapeutics' Change in Receivables stood at $1.2 million in 2021, then surged by 1329.83% to $17.0 million in 2022, then fell by 1.86% to $16.7 million in 2023, then tumbled by 81.59% to $3.1 million in 2024, then crashed by 721.28% to -$19.1 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Change in Receivables are -$19.1 million (Q4 2025), -$6.2 million (Q3 2025), and $11.5 million (Q2 2025).